Roth Capital Raises Earnings Estimates for LeMaitre Vascular

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Roth Capital boosted their FY2025 EPS estimates for shares of LeMaitre Vascular in a report issued on Friday, November 7th. Roth Capital analyst K. Bauser now anticipates that the medical instruments supplier will post earnings per share of $2.37 for the year, up from their previous forecast of $2.27. Roth Capital currently has a “Buy” rating and a $108.00 price objective on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share. Roth Capital also issued estimates for LeMaitre Vascular’s Q4 2025 earnings at $0.67 EPS, Q1 2026 earnings at $0.62 EPS, Q2 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $2.56 EPS and FY2027 earnings at $2.76 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. During the same quarter in the previous year, the business earned $0.49 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS.

Other equities research analysts also recently issued reports about the stock. Barrington Research restated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Finally, Wells Fargo & Company dropped their price target on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Stock Up 2.9%

LMAT opened at $90.37 on Monday. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The business has a 50-day moving average of $89.33 and a two-hundred day moving average of $86.96. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 43.87, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, November 20th. LeMaitre Vascular’s payout ratio is currently 34.48%.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its holdings in shares of LeMaitre Vascular by 3.0% during the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock valued at $9,385,000 after purchasing an additional 3,248 shares during the period. US Bancorp DE boosted its stake in LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 368 shares during the period. Northern Trust Corp raised its position in LeMaitre Vascular by 5.4% during the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after buying an additional 17,748 shares during the period. Congress Asset Management Co. grew its holdings in shares of LeMaitre Vascular by 4.6% during the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after acquiring an additional 29,553 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $892,000. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.